EphB4 is a receptor tyrosine kinas e that is expressed on epithelial cells during fe tal life. It is also expressed on some venous endothelial cells. We conducted a study of six men with primary squamous cell carcinoma of the head and neck (HNSC C) that had metastasized to the cervical lymph nodes. Our goal was to determine ifEphB4 is aberrantly expressed in cases ofHNSCC and to determine if there is a qualitati ve difference between the expression of EphB4 on primary and metastatic tumors and its expression on normal mucosa adja cent to primary tumors. From each patient, we obtained speci mens ofthe prima ry tumor, the nodal metastasis, and the adj acent normal mucosa, and weperform ed immunocytochemistry on each. We obse rved EphB4 expres sion in all primary and metastatic tumors and no expression in the normal tissue. In each of the six pat ients, expres sion was greater in the metastatic tumor than in the primary tumor. We conclude that EphB4 is a novel target in the treatment of HNSCC.
Introduction
Squamous cell carcinoma, the mo st common cancer of the head and nec k, is cau sed primarily by tob acco-derived carcino gens. 1 Head and neck squamous cell carcinoma (HNSCC) ha s been shown to progress through a series of dyspl astic histopathol ogic chan ges before it becomes an invasi ve cance r. Th e differences seen in normal epithelium in the upper aerodigestive tract and in cancer cells that arise from that tissue are the result of mut ation s in specific genes and alterations of their ex pression.' These genes cont rol a vari ety of cellular proc esses, including Behdad Parsa, BS Rizwan Masood, PhD Parkash S. Gill, MD proliferation and immortalization . Both the activation of oncogenes and the inact ivation of tumor suppressor proteins are involved in these pathways.
Receptor tyrosine kin ases have been widely implicated in the gene rat ion and progres sion of common hum an tumors, including HNSCC. 3 One of these kinases is the epid erm al growth facto r (EGF) receptor (EGFR) gen e, which encodes a tran smembrane receptor for EGF-family ligands. In HNSCC, EGFR and/or EGF ligand are overexpressed.' > The largest subfamily of receptor tyro sine kin ases is the Eph family, which has 14 fully sequenced mernbers.sThe prototype of this gene family (EphA I) was isolated from an erythropoietin-producing hepatoma cell line. Initially, the ligand s for the se receptors were unknown, but they have since been identified . The Eph-family ligand s are called ephrins (for Eplt receptor interacting proteins).
Th ese ligands, like the receptors, are anchored on the plasm a membrane via a glycosyl pho sphatidylinositol linkage (eph rin-A) or a tran smembrane dom ain (ephrin-B).? The binding of ephrins to Eph s requires cell-to-cell cont act; soluble form s of ephrins ca nnot acti vate their receptors . To date , eight ephrins have been cloned, and each is cap able of binding to several rece ptors."
Both Eph s and ephrins are divided into two subclass es-A and B-on the basis of their sequence hom ology , struc ture, and binding affinity. Although initially characteri zed in the ner vou s system," recent knock-out studies have suggested that eph rin-B 2 and its EphB4 receptor play key role s in vascul ar development ." For exampl e, mou se embryos that lack ephrin-B2 and EphB4 exhibit fatal defect s in early angiogenic remodelin g. Moreover, ephrin-B2 and EphB4 displ ay remarkably reciprocal distribution patterns during vascular dev elopment, with ephrin-B2 marking the endothelium of prim ordi al arterial vessels while EphB4 marks the endothelium of primordial venous vesse ls.Th ese distribution s sugges t that ephrin-B2 and EphB4 are invol ved in establishin g arteria l vs venous identity, perhaps by fusing arterial and venous vessels at theirjunctions. Defects in these proc esses might • Excellent coverage of Gram+ and Gram-pathogens' *Other first-linetreatment options for mild to moderate disease include amoxicillin, amoxlclav ER, telithromycin, or other cephalosporins. Pseudomembranous colitis has been report ed wi th nearly all antibacterial agents, including cefdinir, and mayrange in severity Irom mild· toIife·threatening. Therefore, it is important toconsider thisdiagnosis in patients who present with diarrhea subsequ ent to the administration ofantibacterial agents.
" ...quinolones should not be used as first-line agents in the treatment of acute bacterial sinusitis because of the potential for development of bacterial resistance." 3
Treatment wi th antibacterial agents alters the normal flora of the colonand may permit overgrowth of clostridia. St udies indicate that a toxinprodu ced by Clostridiumdifficile isaprimarycauseof"ant ibioticassociated colitis."
After the di agnosis of pseudomembranous colitis has been established, appropriate therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to drug di scontinuation alone. In moderateto severe cases, considerationshould be given to management withfluids and electrolytes, protein supplementation. and treatment with an antibacterial drug clinically effective agai nst Clos/ridiumdiffi cile. PRECAUTIONS: General : As with other broad-spectrum antibiotics, prolonged treatment may result in the possibl e emergence and overgrowth of resi stant organisms. Car eful observation of the patient is essenti al. If superinfectionoccursduringtherapy. appropriatealternative ther apy should be administered.
Cefdinir, as with ot her broad-s pectrum antimi crobials (antibiotics), should beprescribed wit hcautioninindividualswithahi storyof colitis.
Inpatientswithtransient orpersistent renal insufficiency(creatinine clearance <30 mUmin), the tot al dail y dose of OMNI CEFshould be reducedbecausehi gh andprol ongedplasma concentrations of cefdini r can result fol lowing recommended doses. Information forPatients: Antacids containingmagnesiumoraluminum interferewiththe absorptionof cefdini r. Ifthistype of antacidisrequir ed during OMNICEFtherapy, OMN ICEFshould be taken at least 2 hours beforeoraltertheant acid.
Iron supplements. including multi vit amins that contain iron, interfere with the absorption of cefdi ni r. If iron supplements are re quired during OMNICEFtherapy, OMNICEFshould be taken at least 2 hours bef ore or afterthe supplement.
Iron-fortified inf ant formuladoes notsignificantly int erfer ewiththe absorptionofcefdinir. Theref ore, OMNICEFfor Oral Suspensioncanbe administered wi th iron-fortified infant formula.
Diabeticpatient sandcaregiversshouldbe awarethat theoral suspension contains 2.86 gof sucrose perteaspoon. Orug Interactions: Antacids: (aluminum-or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules wi th 30 mL Maal oX® TCsuspension reduces the rate (Cm ,,) and extent (AUC) of absorptionbyapproximately 40%. TimetoreachCm " isalso prolonged by 1 hour . Ther eare nosi gnificant effects on cefdinir pharmacoki net ics if theantacid is administere d2 hoursbefore or 2 hoursafter cefdini r. If antacids are required during OMNICEF therapy, OMNICEF should be takenat least2hours beforeoralter theantacid.
Probenecid: As with other~-I a c t am antibiotics, probenecid inhibi ts therenal excretion ofcefdinir, resulting inanapproximate doubl ing in AUC, a 54% increase in peak cefdinir plasma levels, and a 50% prolongation intheapparent eliminationt~.
Iron Supplements and Foods Fortified WithIron: Concomitant administration of cefdinir withather apeut iciron supplementcontaining 60mgof elemental iron (as FeSO,) or vitamins supplemented with 10 mg of elemental iron reducedextent ofabsorptionby80% and 31%. respectively. If ironsupplements arerequired during OMNICEFtherapy, OMNICEF should betaken at least 2hoursbef oreorafter the supplement.
TheeHectoffoods highly fortified withelemental iron (primarily ironfortified breakfastcereals) oncefdinirabsorption has not been studied.
Concomi tantly administered iron-fort ifi ed infant formul a (2.2 mg elemental ironl 6oz) hasnosignificant effect oncefdini r pharmacokinetics.
03H-033-9228-1 PRINTED INU.S.A. be possibly,probably, or definitely associated withcefdinirtherapy. Discontinuationswereprimarilyforgastrointestinal di sturbances,usuallydiarrhea. Fiveof 2289 (0.2%) patientswere di scontinued duetorash thought rel at ed tocefdi ni r administration.
In the US, thefollowing adverse events werethought by investigators to be possibl y, probably, or definit el y rel ated to cefdinir suspension in multiple-dose clinical trials (N; 1783 cefdinir-treated patients [977 males and 806 females]): 1) Incidence;:,1%: diarrhea (8%), rash (3%), vomi ting (1%); 2) Incidence<1% but >0.1%: cutaneous moniliasis (0.9%), abdominal pain (0.8%), leukopenia' (0.3%), vaginal moniliasi s (0.3% of gi rls), vagini tis (0.3% of gi rls), abnormal stool s (0.2%), dyspepsia (0. 2%), hyperkinesia (0.2%), increased ASP (0.2%), maculopapular rash (0.2%), nausea (0. 2%) . (' Laboratory changes were occasionally reported as adverse events.) NOTE: In both cefdinir-and control-treat ed patients, rat es of diarrhea and rash were higherintheyoungest pediatric pati ents. Theincidenceof diarrheaincefdinir-treated patients~2 yearsof age was 17% (95/557) compared with4%(51/1226) inthose>2years old.Theincidence of rash (primarily diaper rash intheyounger patients) was 8% (43/557) in patients~2 years of age compared wi th 1% (8/ 1226) in those>2yearsold.
Thefollowing laboratoryvaluechanges ofpossibl ecli nical significance, irrespective ofrelationship totherapy withcefdinir, were seenduringcli nical tri als conducted in the US in 1783 pediat ric pat ients: 1) Incidence ;:,1%: i lymphocytes (2%), ia lkaline phosphatase (1%), I bcarbonate' (1%), ieosinophils(1%), ilactate dehydrogenase(1%), Tpl atelets(1%), i PMNs (1%), !P MNs ( 1%), i urineprotein(1%); 2) Incidence <1% but >0.1%: Tphosphorus (0.9%), i urine pH (0.8%), ! lymphocyt es (0. 8%), !w hi te blo od cells (0.7%), ! calcium' (0. 5%), ! h emogl obin (0.5%), iurine leukocyt es (0.5%), Tmonocytes (0.4%), Iphosphons (0.4%), iA ST(0.3%),Tpotasslum' (0.3%),iu rinespecific gravi ty(0.3%), iw hite blood cells(0.3%), dhernatocrit-(0.2%), Iurine specificgravity(0.1%).
(' N; 1387 fortheseparameters.) Postmarketing Experience: The following adverse experiences and al tered laboratorytests, regardlessof their relat ionshiptocefdinir, have been reported during extensive postmarket ing experience, beginning wi thapproval inJapan in 1991 : Stevens-Johnsonsyndrome, toxic epidermal necrolysis,exfoliat ive dermatiti s,erythema multiforme,erythema nodosum, conjunctivitis, stomat itis, acute hepatitis, cholestasis, fulminant hepat itis, hepati c failure, jaundice, increased amylase, shock, anaphylaxi s, facial and laryngeal edema, feeling of suffocation, acute enterocolitis,bl oodydi arrhea,hemorrhagi ccolitis, melena,pseudomembranous colitis,pancytopenia, granulocytopenia, leukcpena, thrombocytopenia, idi opathic thrombocytopenic purpura, hemolyti c anemia. acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, idiopathic interstitial pneumonia, fever, acute renal failure, nephropathy, bl eedingtendency, coagulation di sorder, disseminated intravascular coagulation, upper GI bl eed, peptic ulcer, ileus, loss of consci ousness, allergic vasculitis, possible cefdinir-diclofenac interaction, cardiac failure, chest pain, myocardial infarction, hypertension,involuntarymovements, and rhabdomyol ysi s. Cephalosporin Class Adverse Events: The fol lowing adverse events and altered laboratory tests have been reported for cephalosporinclass antibi otics in gener al: Allergic reactions, anaphylaxis, Stevens-Johnsonsyndrome, eryt hema mul tiforme. toxic epidermal necrolysis, renal dysfunction, toxi c nephr opathy, hepati c dysfunction including cholestasis, aplastic anemia, hemolytic anemia, hemorrhage, fal seposit ive test for urinary glucose, neutrop enia, pancytopenia, and agranulocytosis. Pseudomembranous colitis symptoms may begin during or aft erantibiotictreatment(see WARNINGS).
Several cephalosporins have been implicat ed intrigg ering seizures, particularl y inpatientswi threnalimpai rment whenthedosagewas not reduced (seeOVERDOSAGE). If seizures associatedwithdrugtherapy occur, thedrugshould bedi scontinued . Anti convulsant therapycanbe given if clinicallyindi cated. OVEROOSAGE: Information on cefdi ni r overdosage in humans is not available. Inacute rodent toxi citystudies, asi ngle oral 5600-mglkg dose produced noadverse effects. Toxic si gns and symptoms foll owing overdosagewi th other~-I a c ta m antibiotics have included nausea, vomiting, epigastric di st ress,diarrhea,and convulsions.Hemodi alysisremoves cefdi nir from the body. This may be useful in the event ofa serious toxic react ionfromoverdosage, particularly if renal functioniscompromised. Ther efore, OMNICEF for Oral Suspension can be administered with ironfortified inf ant formula.
Therehave beenreports of reddishstoolsinpatientsreceivingcefdini r. Inmany cases, patients werealso receiving iron-containingproducts. The reddish color isdue tothe formationof anonabsorbablecomplex between cefdini r oritsbr eakdown product s and ironinthe gastrointestinal tract. Orug/Laboratory TestInteractions: Afalse-positive reactionfor ketones intheurine may occurwithtestsusi ngni troprussi de, butnot wit hthose using nitroferricyanide. The admi nist ration of cefdinirmay result in a false-positive reaction for gl ucose in urine using ClinitesJ®, Benedict's solution, or Fehling's solution. It is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as ClinistiX® or Tes-Tape®) be used. Cephalosporinsare knownto occasionallyinduce apositivedirect Coombs' test. Carcinogenesis, Mutagenesis, Impairment ofFertility: Thecarcinogenic potential of cefdinirhas not been evaluated.No mut ageniceffects were seen inthe bacter ial reversemutation assay (Ames) or point mutation assay at the hypoxanthine-guanine phosphoribosyltransferase locus (HGPRT) in V79 Chinese hamster lung cells. No clast ogenic effects were observed invitro inthe st ructural chromosome aberration assay inV79 Chinese hamster lungcells orinvivointhe micronucleusassay inmousebone marrow. Inrats,fertilityand reproductiveperformance were not affectedbycefdinir atoral doses up to1000 mglkg/day (70times the human dosebased on mglkg/day, 11timesbasedon mg/m' /day). Pr egnancy -Terat ogenic Effects: Pregnancy Category B: Cefdinir was notteratogenic inrats at oral doses up to1000mglkg/day (70times the human dose based on mglkg/day, 11 times based on mg/m'/day) orin rabbits at oral doses up to 10 mglkg/day (0.7 times the human dose based on mglkg/day, 0.23 times based onmg/m' /day ). Maternal toxi ci ty (decreased body wei ght gain)was observed inrabbifsat the maximum tolerated dose of 10 mglkg/day wit hout adverse eHects on offspring. Decreased bodyweight occurred inrat fetuses at ;:,10 0mglkg/day. andin rat offspring at ;:,32 mglkg/day. No effects were observed on maternal reproductive parametersoroffspring survival, development, behavior, or reproductivefunction.
There are, however, no adequate and well-controlled studies in pregnantwomen. Becauseanimal reproductionstudies are not always predictive of human response, thi s drug should be used du ring pregnancy only if clearlyneeded . Labor andOelivery: Cefdinir has not been studied for useduring labor and delivery. Nursing Mothers: Following administration of single 600-mg doses, cefdini r was not detected inhuman breast milk. Pediatric Use: Safety and efficacy in neonat es and infant s less than 6 months of age have not been established. Use of cef dinirfor the treatment of acute maxillary sinusitis in pedi atric pati ents (age 6 monthsthrough 12 years) is supporte d by evidence fromadequate and well-controlled studies in adults and adolescents, the similar pathophysiology ofacute sinusitisin adult and pediatric patients, and comparative pharmacokineticdat ainthepediatr ic populat ion. Geriatric Use: Efficacy is comparable in geriatric patientsand younger adults.Whilecefdi nir has been well-tolerated inall age groups, inclinical trialsgeriatricpatientsexperiencedalower rateof adverse events, including di arrhea. than younger adults. Doseadjustmentinelderlypatients is not necessaryunl essrenal funct ion ismarkedly compromised. ADVERSE EVENTS: ClinicalTrials-OMNICEF Capsules (Adult and Adolescent Patients): In clinical tri als, 5093 adultand adolescent patients (3841USand1252non-US) were treatedwiththerecommendeddose of cefdinir capsules (600 mg/day). Most adverse events were mild and self-limiting. Nodeaths orpermanent disabilities were attributed tocefdini r. One hundred forty-seven of5093 (3%) patientsdi scontinued medication due toadverse eventsthought bytheinvestigatorstobepossibly,probably, or definitely associated wi th cefdinir therapy. The discontinuations were primarily for gastrointestinal disturbances, usually diarrhea or nausea. Nineteen of 5093 (0.4%) patients were di scontinued due torashthought relatedtocefdini radministration.
Inthe US,thefollowing adverse events were thought by investigatorstobe possi bl y, probab~, ordefinitely related tocefdinircapsules inmultiple-dose clinical trials in adult and adolescent patients (N ; 3841 cefdinir-treated patients[1733malesand2108females)):1) lncidercezt%:di arrhea(15%), vaginal moniliasi s(4%ofwomen),nausea(3%), headache(2%),abdominal pain (1%), vaginilis (1 % ofwomen); 2) Incidence <1 % but >0.1%: rash (0.9%), dyspepsia (0.7%), flatulence (0.7%), vomiting (0.7%), abnormal stools (0.3%), anorexia (0.3%), constipation (0.3%). dizziness (0.3%): dry mouth (0.3%), asthenia (0. 2%), insomnia (0.2%), leukorrhea (0.2% of women), moniliasis(0.2%). pr uritus(0.2%),somnolence (0.2%).
Thefollowinglaboratoryvalue changes of possibleclinical significance, irrespective of relationship to therapy with cefdinir , were seen during clinical trialsconducted intheUSin3841adul t andadolescent patients: 1) Incidence ;:,1%: i urineleukocyt es (2%). i urine protein(2%), i gammaglutamyltransferase' (1 %), !Iy mp hocytes (1%), i microhematuria (1%); 2)Incidence<1%but >0.1%: i glucose' (0.9%), i urine glucose(0.9%), i white blood cells(0.9%), ! whiteblood cells (0.7%), i alanine aminotransferase (AU) (0.7%), ieosinophils (0.7%), i urine specific gravity (0.6%), ! ur ine specific gravity' (0.2%), !bicarbonate' (0.6%), i phosphorus (0.6%), ! phosphorus' (0.3 %), i aspartate aminotransferase (AST) (0.4%), i alkaline phosphatase (0.3%), i blood urea ni trogen (BUN) (0.3%), ! hemoglobin ( 0.3%), i polymorphonuclear neutrophils (PMNs) (0.3%), ! PMNs (0.2%), i bilirubin (0.2%), ilact at e dehydrogenase' (0.2%), i lymphocyt es (0.2%), Tplatelets (0.2%). i potassium' (0.2%), i urinepH' (0.2%). (' N<3841for these par ameter s. EXPRESSION OF EpHB4 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA account for the early lethality observed in mouse embryos that lack these proteins."
EphB4 is also expressed on epithelial cells . Ectopic expression of EphB4 in the breast tissue of transgenic mice shows cooperative tumor induction and metastasis with neuT antigen. Preliminary studies have identified expression of the EphB4 gene in a number of human tumors, including hematologic malignancies, melanomas, glioblastomas, and lung, breast, and colon carcinomas. However, data on EphB4 protein levels are limited, and there is a complete lack of data on the significance of this protein in tumor biology. Also, little is known about the expression and role of the ephrin-Eph system in HNSCC.
In this article, we describe our investigation of the pattern of EphB4 expression in a series of specimens obtained from human primary HNSCC tumors, cervical lymph node metastases, and normal mucosal tissue.
Patients and methods
Our study was conducted at the Keck School of Medicine at the University of Southern California in Los Angeles following approval from the university's institutional review board. Our study population was made up of six men, aged 38 to 77 years (mean : 59), who had stage IV HNSCC; there were three cases of tonsillar fossa squamous cell carcinoma and one each of laryngeal, tongue, and buccal squamous cell carcinoma. All six patients had cervical lymph node metastases.
Tissue harvest and preservation. Tissue specimens were harvested from three sites in each patient-from the primary tumor, from the clinically involved regional metastatic lymph node, and from normal tissue adjacent to the primary tumor. Each specimen was cut into two parts. One part was placed in a sterile container in dry ice, snap-frozen in liquid nitrogen, and stored at -80 0 C. The other part was left unfrozen, fixed in formalin , and analyzed on hematoxylin and eosin staining (H&E) to establish the diagnosis of HNSCC. All tissues were processed immediately following harvest.
Immunohistochemical analysis offrozen-tissue specimens . The tissue blocks of the frozen specimens were sectioned at 5 urn of thickness in a cryostat, mounted on positively charged Superfrost slides (Fisher Scientific; Houston), and air-dried for 30 minutes. Tissues were fixed in cold acetone for 5 minutes and in 1:1 acetone/ chloroform for 5 minutes and then washed with phosphate-buffered saline (PBS) three times for 3 minutes each time. The slides were preincubated with a blocking buffer (0.2 % Triton-XlOO and 1% BSA in PBS) for 20 minutes. The tissues were then incubated with antibodies to EphB4 (l : 100 dilution in PBS) in the blocking buffer at 4 0 C for 16 hours .
After three more washes , the slides were incubated with the appropriate fluorescein-conjugated secondary anti- For histopathologic study, the adjacent sections were stained with H&E . Both immunofluorescence and H&E staining were performed on each section of primary tumor, metastatic tumor, and normal mucosa.
Results
Expression of EphB4 as seen on immunofluorescence staining of the primary tumor ( figure, A) , metastatic tumor (figure, B), and normal tissue (figure, C) was compared with that seen on H&E staining of the adjacent sections (figure, D, E, and F, respectively).
Primary tumorspecimens. EphB4 expression was seen
on immunofluorescence staining of the primary tumor specimens obtained from all six patients. EphB4 expression was localized in the tumor and not in the stromal component ( figure, A) . The greatest signal intensity was seen at the leading edge of the tumor. On H&E staining, the primary tumor specimens exhibited areas of tumor adjacent to areas of the stromal component ( figure, D) .
Metastatic tumor specimens. Expression of EphB4
was detected in the metastatic nodes obtained from all six patients. On immunofluorescence staining, the EphB4 signal was limited exclusively to the tumor itself; normal areas of the lymph nodes exhibited no signal (figure, B) . In each case, the intensity of immunofluorescence staining of EphB4 in the metastatic tumor was higher than that of the primary tumor. H&E staining confirmed tumor morphology in the metastatic specimens (figure, E).
No evidence of EphB4 expression on immunofluorescence staining (figure, C) or tumor on H&E staining (figure, F) was seen in the normal tissue specimens obtained from any patient.
Discussion
The observation that angiogenesis occurs around tumors was made nearly a century ago." In the 1970s, an intense search for pro-and antiangiogenic molecules was spawned by the hypothesis that tumor growth and metastasis are angiogenesis-dependent." It is now widely accepted that the "angiogenic switch" is "off" when the effect of proangiogenic molecules is balanced by that of antiangiogenic molecules, and the switch is "on" when the net balance is tipped in favor of angiogenesis." Various factors that trigger this switch have been discovered. They include metabolic stress (e.g ., low POz or low pH), mechanical stress (e.g ., pressure generated by proliferating cells), response to immune and/or inflammatory cells that have Figure. Upper panel shows the results ofEph B4 immunofl uorescence staining ofthe p rimary tumor (A) , metastatic cerv ical lymph node (B) , and normal mucosa (C). Lower panel shows the result s ofH &E staining fo r tumo r morph ology in the primary tumo rill), the metastasis (E) , and normal tissue (F) . Note the higher intensity ofthe EphB4 staining in the lymph node than in the p rimary tumo r and the lack ofstaining in the norma l mu cosa. infiltrated tis sue , and genetic mutations (e.g ., activation of oncogenes or del etion of tumor-suppressor gene s that control the production of angiogenesis regulators). 18 The means by which the interplay among enviro nmental and genetic mechanism s influences tumor angiogenesis is a complex and largely unre solved matter.
Tumors and metastases may arise as small avascular masses that subsequently induce the angiogenic ingrowths that are required to allow for fur ther gro wth of early tumors.P'Ihese tumors are init ially separated fro m und erlyin g vessels by a basement membrane th at must be broken before tumor ce lls can gain access to the vas culature. How ever, rec ent studies indicate that tum or ce lls can initi ally "home in on " and grow by co-opting existin g host ves sels and thu s start off as well -vascularized sma ll tumors." Angiopoietin 2 (Ang2) and vascular EGF (VEGF) inductions correl ate remarka bly well with thi s process. Soon after tumor co-opt ion , host ves sels begin express ing high autocrine levels of An g2. T hus, An g2 is one of the earl iest tumor markers describe d ; it is also one ofthe most general because it marks co-opted vessel s and not the tumor cells themselves. Overe xpression of An g2 destabilize s vessels and enhances apoptotic processes. As vessels die, the tumor becomes avascular and hyp oxic, resul ting in a mark ed indu ction of tumor-deri ved VEGF. Th ese high levels ofVEGF prompt the on set of robu st angio genesis that spro uts from host vessels and allows for tumor survival and fur ther growth.
Se veral studies hav e shown that a high expression of 870 ephrins may be ass ociated with an increased potential for tum ori gen esis, including grow th and met astasis.I'"!" Upregulation of ephrins during tum or progression is mediated by sev era l mechanisms. The EphA2 rec eptor has been found in so me tum or-associated endothe lial ce lls.'? Tumor necrosis facto r alpha and interleuki n I-beta, which are produced by leukocyt es, indu ce ephrin-A I in melan omas as host infl ammato ry respons es to tum or. 10 Me mbers of the Eph receptor gen e family and their ligand s faci litate ce ll-ce ll repul sion (antiadhes ive) and prom ote ce ll migration. Overexpr ession of ephrin-B2 and EphB4 has been observed in malignant col onic epithelium."
Our stud y dem on strated overe xpression of EphB4 in primary HNSCC and cer vica l lymph node metastases. Expression wa s grea ter in the metastatic lym ph nodes than in the primary tum ors, as ev ide nced by the grea ter intensity of immunofluorescenc e staining of EphB4 in the lymph nodes. Although our study did not dem onstrate it, EphB4 may play a rol e in lymphatic metastasis of HNSCC. 14 ,2 1. 23 We are curre ntly investigatin g the quantitati ve differences in the ex pression ofEphB4 with respect to tum or characteristics, induction of EGFRs, inactivation of tumor suppr essor genes , and ac tiva tion of oncogenes. We are also interested in definin g the role that EphB4 play s in the developm ent and metastasis ofHNSCC. It is apparent that EphB4 can be used as a no vel target for treatment del ivery in re fractory HNSCC. Ep hB4 inhib itors would be of therapeutic value if Eph B4 can be prove n to enhance tum or grow th or spread . 
